Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
暂无分享,去创建一个
Paul A Dayton | Russell J Mumper | Anush Sridharan | D. Hazuda | M. Swanson | R. Mumper | P. Dayton | P. Ho | Martina Kovarova | A. Sridharan | A. Kashuba | Daria J Hazuda | Angela D M Kashuba | C. Sykes | S Rahima Benhabbour | Clinton Jones | Daijha J Copeland | Roopali Shrivastava | Michael D Swanson | Craig Sykes | Phong T Ho | Mackenzie L Cottrell | Samantha M Fix | Orrin Thayer | Julie M Long | J Victor Garcia | M. Kovárová | J. Victor Garcia | S. R. Benhabbour | Roopali Shrivastava | Julie M. Long | A. Kashuba | M. Cottrell | Clinton L. Jones | Orrin Thayer | Daria J. Hazuda | Daijha J. Copeland | Michael D. Swanson | Phong T. Ho | Julie M. Long | Paul A. Dayton
[1] G. Betageri,et al. Effect of Co-Solvents on the Controlled Release of Calcitonin Polypeptide from In Situ Biodegradable Polymer Implants , 2005, Drug delivery.
[2] Mohammad Erfan,et al. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. , 2009, Journal of pharmaceutical sciences.
[3] H. Vinters,et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.
[4] Chun-Wen Hsiao,et al. An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy. , 2016, Journal of the American Chemical Society.
[5] John D. Schreier,et al. Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. , 2016, Journal of Medicinal Chemistry.
[6] I. Singh,et al. Atrigel: A potential parenteral controlled drug delivery system , 2010 .
[7] A. McHugh,et al. Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[8] S. Pekamwar,et al. High-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Method for the Quantitative Estimation of Dolutegravir Sodium in Bulk Drug and Pharmaceutical Dosage Form , 2015, Scientia pharmaceutica.
[9] Sabine Kempe,et al. In situ forming implants - an attractive formulation principle for parenteral depot formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[10] R. Berges,et al. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer , 2006, Current medical research and opinion.
[11] Tom O. McDonald,et al. Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. , 2017, Nanoscale.
[12] A. McHugh,et al. The role of polymer membrane formation in sustained release drug delivery systems. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[13] K J Brodbeck,et al. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[14] Christoph van Thriel,et al. Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[15] Hamid Mobedi,et al. Effect of additives on release profile of leuprolide acetate in an in situ forming controlled‐release system: In vitro study , 2008 .
[16] Nureddin Ashammakhi,et al. Temporal control of drug release from biodegradable polymer: multicomponent diclofenac sodium releasing PLGA 80/20 rod. , 2009, Journal of biomedical materials research. Part B, Applied biomaterials.
[17] M. Fakhree,et al. Review of pharmaceutical applications of N-methyl-2-pyrrolidone. , 2010, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[18] I. Rupenthal,et al. Injectable implants for the sustained release of protein and peptide drugs. , 2013, Drug discovery today.
[19] David S Jones,et al. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[20] H. Ding,et al. Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages , 2011, Journal of Virology.
[21] Luis Solorio,et al. The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants. , 2015, Journal of pharmaceutical sciences.
[22] Luis Solorio,et al. Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure. , 2015, Journal of pharmaceutical sciences.
[23] W. Cui,et al. Biomimetic Design of Mussel-Derived Bioactive Peptides for Dual-Functionalization of Titanium-Based Biomaterials. , 2016, Journal of the American Chemical Society.
[24] John D. Schreier,et al. Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. , 2015, Journal of medicinal chemistry.
[25] A. Perelson,et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.
[26] Luis Solorio,et al. Noninvasive Characterization of the Effect of Varying PLGA Molecular Weight Blends on In Situ Forming Implant Behavior Using Ultrasound Imaging , 2012, Theranostics.
[27] M. Boffito,et al. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection , 2016, Therapeutic drug monitoring.
[28] A. Sambrone,et al. Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits , 2014, Xenobiotica; the fate of foreign compounds in biological systems.
[29] Hirenkumar K. Makadia,et al. Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .
[30] M. Rathbone,et al. Long Acting Animal Health Drug Products: Fundamentals and Applications , 2013 .
[31] Hui Xu,et al. The Anti-Melanoma Efficiency of the Intratumoral Injection of Cucurbitacin-Loaded Sustained Release Carriers: In Situ-Forming Implants , 2015, AAPS PharmSciTech.
[32] J. Leroux,et al. N-methyl pyrrolidone/bone morphogenetic protein-2 double delivery with in situ forming implants. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[33] D. Burgess,et al. Long Acting Injections and Implants , 2012, Advances in Delivery Science and Technology.
[34] B. Wynne,et al. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults , 2017, Clinical pharmacology in drug development.
[35] A. Klibanov,et al. Dual functional polyelectrolyte multilayer coatings for implants: permanent microbicidal base with controlled release of therapeutic agents. , 2010, Journal of the American Chemical Society.
[36] A. Boudier,et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[37] G. Learn,et al. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis , 2013, Retrovirology.
[38] M. Swanson,et al. Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice , 2012, PLoS pathogens.
[39] Hongtao Xu,et al. Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.
[40] Trevor Coward,et al. An In-Vitro Study , 2016 .
[41] Jagdish Singh,et al. Smart polymer based delivery systems for peptides and proteins. , 2007, Recent patents on drug delivery & formulation.
[42] R. Desrosiers,et al. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission , 2015, PLoS pathogens.
[43] R. Mumper,et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.
[44] J. Kost,et al. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. , 2000, Journal of biomedical materials research.
[45] R. Zeldin,et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.
[46] A. Kashuba,et al. Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women , 2013, Antiviral therapy.
[47] Luis Solorio,et al. Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging , 2012, Drug Delivery and Translational Research.
[48] O. Katare,et al. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor. , 2012, International journal of pharmaceutics.
[49] Luis Solorio,et al. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. , 2010, Journal of biomedical materials research. Part A.
[50] M. Wainberg,et al. Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions , 2015, Journal of Virology.
[51] P. D. Graham,et al. Phase inversion dynamics of PLGA solutions related to drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[52] M. Wainberg,et al. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance , 2015, Journal of Virology.
[53] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.